Compile Data Set for Download or QSAR
maximum 50k data
Found 266 of ic50 for UniProtKB: P09936
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445080((S)-2-(4-(5-(Trifluoromethyl)-1H-pyrazol-4-yl)indo...)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445088((S)-2-(4-(1H-pyrrolo [2,3-b]pyridin-3- yl)indoline...)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445090((2S,4S)-4-fluoro-2-(4-(5-(trifluoromethyl)-1H-pyra...)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445149((2S,4S)-4-Fluoro-2-(4-(5-methyl-1H-pyrazol-4-yl)in...)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445158((S)-2-(5-(3-(trifluoro- methyl)-1H-pyrazol-4- yl)i...)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445160((S)-2-(4-(1H-pyrrolo[2,3-b]- pyridin-4-yl)indoline...)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445080((S)-2-(4-(5-(Trifluoromethyl)-1H-pyrazol-4-yl)indo...)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445088((S)-2-(4-(1H-pyrrolo [2,3-b]pyridin-3- yl)indoline...)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM552974((2S,4S)-4-fluoro-2-(4-(5- | US11319287, Example 29)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445149((2S,4S)-4-Fluoro-2-(4-(5-methyl-1H-pyrazol-4-yl)in...)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445158((S)-2-(5-(3-(trifluoro- methyl)-1H-pyrazol-4- yl)i...)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445160((S)-2-(4-(1H-pyrrolo[2,3-b]- pyridin-4-yl)indoline...)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM50589875(8RK64)
Affinity DataIC50:  230nMAssay Description:Inhibition of UCHL1 (unknown origin) using Ub-AMC as substrate preincubated with enzyme for 1 hr followed by substrate addition and measured for 1 hr...More data for this Ligand-Target Pair
In DepthDetails PubMed
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM50594734(CHEMBL5191704)
Affinity DataIC50:  230nMAssay Description:Inhibition of UCHL1 (unknown origin) using Ub-Rho-morpholine as substrate preincubated for 30 mins followed by substrate addition by fluorescence bas...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM50589875(8RK64)
Affinity DataIC50:  230nMAssay Description:Inhibition of UCHL1 (unknown origin) using Ub-Rho-Morpholine as substrate preincubated with enzyme for 1 hr followed by substrate addition and measur...More data for this Ligand-Target Pair
In DepthDetails PubMed
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445081((S)-2-(4-(1H-Pyrazol-4-yl)indoline-1-carbonyl)pyrr...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM50590283(CHEMBL5169766 | US20230303547, Reference Example D)
Affinity DataIC50:  550nMAssay Description:Inhibition of FLAG-tagged UCHL1 (unknown origin) expressed in CAL-51 cells using HA-Ub-VME as substrate incubated for 30 mins by HTRF assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445086((S)-2-(4-(3,5-dimethyl- 1H-pyrazol-4-yl)indoline- ...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445089((S)-4,4-difluoro-2-(4-(5-(trifluoromethyl)-1H-pyra...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445091((S)-4,4-difluoro-2-(4-(5-methyl-1H-pyrazol-4-yl)in...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445098((S)-2-(4-(3-cyclopropyl-1H- pyrazol-4-yl)indoline-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445099((S)-2-(4-(2-aminopyrimidin- 4-yl)indoline-1- carbo...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445100((S)-2-(4-(Pyridin-4-yl)indoline-1-carbonyl)pyrroli...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445107((S)-1-Cyano-N-(4-(2-methoxyphenyl)thiazol-2-yl)-N-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445108((S)-1-cyano-N-(4-(3- methoxyphenyl)thiazol-2- yl)-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445113((S)-N-(4-(3-chlorophenyl)- thiazol-2-yl)-1-cyano-N...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445114((S)-N-(4-(2-chlorophenyl)- thiazol-2-yl)-1-cyano-N...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445115((S)-1-cyano-N-methyl-N-(4-phenylthiazol-2-yl)pyrro...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445132((2S,4S)-1-Cyano-4-methoxy-N-methyl-N-(4-phenylthia...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445135(4-(1-(Cyano-L-prolyl)indolin-4-yl)-1H-pyrazole-5-c...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445137((S)-2-(4-(2-Aminopyridin-4-yl)indoline-1-carbonyl)...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445140((S)-1-cyano-N-(4- (6-methoxypyridin- 2-yl)thiazol-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445145(1-(Cyano-L-prolyl)-N-methyl-4-(1H-pyrrolo[2,3-b]py...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445150(N-(4-(1-(Cyano-L-prolyl)indolin-4-yl)pyridin-2-yl)...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445151((S)-2-(4-(5-(Trifluoromethyl)-1H-pyrazol-4-yl)-2,3...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445155((S)-N-(4-(3-Chlorophenyl)thiazol-2-yl)-1-cyano-N-e...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445159(4-(1-(cyano-L-prolyl)indolin- 4-yl)nicotinonitrile...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445163((S)-2-(4-(2- (methylamino)pyrimidin- 4-yl)indoline...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445165((S)-2-(4-(1H-pyrazolo[3,4- b]pyridin-3-yl)indoline...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445166((S)-2-(4-(5H-pyrrolo[2,3- b]pyrazin-7-yl)indoline-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445167((S)-N-(4-(3-chloro-4- fluorophenyl)thiazol-2-yl)-1...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445169((S)-1-cyano-N-(4-(3- cyanophenyl)thiazol-2-yl)- N-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445081((S)-2-(4-(1H-Pyrazol-4-yl)indoline-1-carbonyl)pyrr...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445082((S)-2-(4-(5-Methyl-1H-pyrazol-4-yl)indoline-1-carb...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445086((S)-2-(4-(3,5-dimethyl- 1H-pyrazol-4-yl)indoline- ...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM552973((S)-4,4-difluoro-2-(4-(5- | US11319287, Example 28)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445091((S)-4,4-difluoro-2-(4-(5-methyl-1H-pyrazol-4-yl)in...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445098((S)-2-(4-(3-cyclopropyl-1H- pyrazol-4-yl)indoline-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445099((S)-2-(4-(2-aminopyrimidin- 4-yl)indoline-1- carbo...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM445100((S)-2-(4-(Pyridin-4-yl)indoline-1-carbonyl)pyrroli...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 266 total ) | Next | Last >>
Jump to: